Making all data publicly available would be welcome

Leonie Segal,* Richard H Osborne,† Susan E Day‡

1 Health Economics Unit, Monash University, PO Box 477, West Heidelberg, Melbourne, VIC 3081.
2 Centre for Rheumatic Diseases, University of Melbourne, Melbourne, VIC.

Correspondence:

1. Segal L, Day S, Chapman A, Osborne R. Priority setting in osteoarthritis. Melbourne: Health Economics Unit, Monash University, April 2003.
2. FDA Medical officers report. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf (accessed Aug 2004).
3. FDA. Statistical Review Briefing Document for the Advisory Committee. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_04_stats.pdf (accessed Aug 2004).
4. FDA Medical Officer’s Gastroenterology Advisory Committee Briefing Document. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf (accessed Aug 2004).
5. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? [editorial]. BMJ 2002; 324: 1287-1288.
6. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits, May 2004. Canberra: DHA, 2004.

Online responses are no longer available. Please refer to our instructions for authors page for more information.